Skip to main content
. 2023 Nov 8;30(4):793–802. doi: 10.1158/1078-0432.CCR-23-0561

Figure 1.

Figure 1. OS in the intention-to-treat and biomarker populations. A, All patients pooled from the MONALEESA-2, -3, and -7 trials. B, Patients with PAM50 analysis of tumor samples. HR, hazard ratio; PBO, placebo; RIB, ribociclib.

OS in the intention-to-treat and biomarker populations. A, All patients pooled from the MONALEESA-2, -3, and -7 trials. B, Patients with PAM50 analysis of tumor samples. HR, hazard ratio; PBO, placebo; RIB, ribociclib.